MENU
+Compare
ADMA
Stock ticker: NASDAQ
AS OF
May 12, 04:59 PM (EDT)
Price
$20.45
Change
+$0.47 (+2.35%)
Capitalization
4.77B

ADMA ADMA Biologics Forecast, Technical & Fundamental Analysis

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases... Show more

Industry: #Biotechnology
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ADMA with price predictions
May 09, 2025

ADMA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on May 09, 2025

ADMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 34 cases where ADMA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADMA advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 256 cases where ADMA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ADMA moved out of overbought territory on April 29, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where ADMA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on May 09, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ADMA as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ADMA turned negative on May 09, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

ADMA moved below its 50-day moving average on May 09, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADMA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ADMA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.771) is normal, around the industry mean (14.703). P/E Ratio (23.786) is within average values for comparable stocks, (64.016). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.990). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (10.672) is also within normal values, averaging (254.016).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ADMA is expected to report earnings to rise 22.48% to 16 cents per share on August 06

ADMA Biologics ADMA Stock Earnings Reports
Q2'25
Est.
$0.17
Q1'25
Missed
by $0.01
Q4'24
Beat
by $0.31
Q3'24
Beat
by $0.02
Q2'24
Beat
by $0.05
The last earnings report on May 07 showed earnings per share of 13 cents, missing the estimate of 14 cents. With 2.27M shares outstanding, the current market capitalization sits at 4.77B.
A.I. Advisor
published General Information

General Information

an operator of a specialty immune globulin, development and commercialization of human plasma and plasma-derived therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
465 State Route 17
Phone
+1 201 478-5552
Employees
624
Web
https://www.admabiologics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RVT14.430.09
+0.63%
Royce Value Trust
FDWM21.990.06
+0.29%
Fidelity Women's Leadership ETF
STPZ53.660.04
+0.07%
PIMCO 1-5 Year US TIPS Index ETF
STXD32.35-0.07
-0.23%
Strive 1000 Dividend Growth ETF
TAIL12.43-0.05
-0.40%
Cambria Tail Risk ETF

ADMA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with TARS. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then TARS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
-15.37%
TARS - ADMA
42%
Loosely correlated
-5.05%
ACLX - ADMA
39%
Loosely correlated
+2.29%
RCUS - ADMA
39%
Loosely correlated
-2.93%
IMTX - ADMA
37%
Loosely correlated
-2.30%
RVMD - ADMA
37%
Loosely correlated
-3.56%
More